The stock saw a fall in short interest of -9.53% as of August 15 ... Brokerages have issued ratings on AMGN recently. July 26 investment analysts at UBS left the company rating at “Neutral” but raised the price expectation to $185.00 from …
This stock lacks the revenue growth potential of some biotech peers, but it also lacks the cash burn and often binary uncertainty. Over the past 15 years AMGN has increased after-tax profit by 16% compounded annually to nearly $9 …
Amgen stock is in the red -- down 2% at $153.44 -- after the company said it no longer expects its experimental osteoporosis drug to win Food and Drug Administration (FDA) approval. Adding insult to injury, Morgan Stanley cut its …
This article is published in collaboration with Scutify, where you can find real-time markets and stock commentary from Robert Marcin, Cody Willard and others. Download the Scutify iOS App, the Scutify Android App or visit Scutify.com. …
Rick Pendergraft: Now that we have entered earnings season, it is important to check the earnings calendar before you invest or make a trade. For instance, Amgen (NASDAQ:AMGN) appeared on my bullish scan yesterday, but I also …
09:02a $AMGN Amgen And Allergan Present Phase 3 Data On Biosimilar Trastuzumab Candi.. 05:55a Somewhat …
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don’t make them change their opinion towards a company. The second half of 2015 and the first …
Amgen Inc. (AMGN) reported second quarter non-GAAP EPS of $3.27 after ... Street expectations are for EPS of $12.48. The stock is now down 4.49 on 142K shares. Amgen traded in a range for the majority of Tuesday's session and closed …
Amgen Inc. AMGN, -1.04% shares dropped 1.9% in morning trade Monday after the company said that it has observed …